AbbVie stock trades up to $234.93 as AbbVie recaps EHA Hematology Congress events

Traders Union
All News
Companies
AbbVie rises 0.07% today

Highlights

ABBV continues a strong uptrend, closing at $234.93, up 8.45% for the week and near 52-week highs.
Momentum indicators signal an overbought market with elevated risk of short-term consolidation or pullback as buying pressure shows signs of exhaustion.
Expected price action for the coming week is range-bound between $234 and $238, with immediate support near $221–$222 and low probability of a significant decline.

Strong uptrend sustained as price lifts above key averages

ABBV is trading at $234.93, which is well above the MA-20 ($221.75), MA-50 ($212.66), and MA-200 ($220.77), confirming a strong uptrend across short, medium, and long-term timeframes. The Ichimoku Kijun level on D1 is at $221.37, currently acting as immediate support, while near-term support sits at MA-20 ($221.75) and key support at MA-50 ($212.66); immediate resistance is marked by the recent weekly high and the next round number levels above the current price.

Bullish momentum tapped out as overbought readings flag exhaustion

Momentum signals are bullish: MACD on D1 indicates a buy and ADX remains neutral with low trend strength. RSI (66), Stoch RSI, and CCI are all in or near overbought territory, signaling buyer exhaustion risks. BBP shows ongoing buyer dominance on D1, while the AO is neutral, not strongly supporting the prevailing trend. ABBV is trading at $234.93, up from $216.63 at last week’s close, for an 8.45% weekly gain, and is positioned at the very top of its weekly range. Weekly volatility stands at 9.23%. The price action reflects a strong upward move and a potential test of resistance, but overbought readings suggest increased probability of consolidation or a near-term pullback.

Further upside likely as consolidation develops near recent highs

For the coming week, the expected price range is $233.96 to $238.02, anchored near the recent 52-week highs but still safely above the 52-week low of $181.73. Based on W1 trend signals—MA-50, W1 RSI, and the lack of strong ADX or MACD signals—the probability of further price increases is high (more than 80%), while the likelihood of decline is very low. The baseline scenario calls for consolidation between $234 and $238 as buying momentum cools. A bullish scenario could see a break above $238, aiming at new highs if momentum overcomes overbought pressures. The bearish scenario is a pullback below $234 toward support at $222–$221 on profit-taking or broader market weakness.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that AbbVie’s upward momentum was supported by strategic acquisitions and product approvals, though overbought conditions suggested a possible period of consolidation. The current analysis confirms this rangebound scenario remains in play, with investors advised to monitor for any breakouts above recent highs as a signal of renewed directional strength.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.